Un campus que no s'atura mai

Seminari VHIR - Dr. Robert Medcalf "Plasminogen activation and stroke: can we predict thrombolysis outcome?"

Desc fecha
Desc info

15:30 h a 17:00 h


Sala d'Actes, planta baixa. Hospital General


Vall d'Hebron Institut de Recerca (VHIR)

Dr. Robert Medcalf,  NHMRC Principal Research Fellow and Director of the Molecular Neurotrauma and Haemostasis Group, Monash, Melbourne 

"Plasminogen activation and stroke: can we predict thrombolysis outcome?"

Robert Medcalf was awarded his Ph.D. from the University of Melbourne in 1984. His first post-doctoral appointment was at the University of Melbourne where he investigated the role of the plasminogen activating system in rheumatoid arthritis. In 1986, he continued his research in Lausanne, Switzerland where he extended his interest in the field of plasminogen activation and fibrinolysis. In 1993, he returned to Australia where he established a laboratory at Monash University in Melbourne. He was appointed as a NHMRC Senior Research Fellow in 2003. He has published more than 90 papers in peer reviewed journals on fibrinolysis and plasminogen activation and has an H-index of 30. Since 2000, his research has attracted more than $7m in peer reviewed funding from the NHMRC, the National Heart Foundation, the Brain Research Foundation and the Victorian Neurotrauma Initiative. He was elected as Chairman of the International Society on Fibrinolysis and Proteolysis (ISFP) in 2004 and in 2008 and he will also be Congress President of the 2019 meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Melbourne. He is Associate Editor of the Journal of Thrombosis and Haemostasis which is the flagship journal of both the ISFP and the ISTH and is on the Editorial Board of the Journal of Biological Chemistry.

Host: Neurovascular Research Group (VHIR) alejandro.bustamante@vhir.org







Comparteix aquest contingut